


ABSTRACT

A prostaglandin derivative represented by the formula:



- wherein X is a halogen atom in the α - or β -position, Y is
- 5 an ethylene group, a vinylene group or an ethynylene group,
 A is a group represented by the formula: $O(CH_2)_n$,
 $S(O)_p(CH_2)_n$,
 $O(CH_2)_qO(CH_2)_r$,
 $O(CH_2)_qS(O)_p(CH_2)_r$,
 10 $S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or
 $S(O)_p(CH_2)_qO(CH_2)_r$
 (wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an
 integer of 1 to 3, and r is 0 or 1),
 R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10}
 15 cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a
 C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl
 group or a bridged cyclic hydrocarbon group,
 R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10}
 cycloalkyl group, and
 20 m is 0, 1 or 2], a pharmaceutically acceptable salt thereof
 or a hydrate thereof.

The present invention is to provide novel PG

derivatives having an excellent PGD₂-like agonistic activity and a sleep-inducing action.